Deo, Darrel R.
Willett, Francis R.
Avansino, Donald T.
Hochberg, Leigh R.
Henderson, Jaimie M.
Shenoy, Krishna V.
Funding for this research was provided by:
Wu Tsai Neurosciences Institute, Stanford University
Howard Hughes Medical Institute
Office of Research and Development, Rehabilitation R&D Service, US Department of Veterans Affairs (A2295R)
National Institute of Neurological Disorders and Stroke (U01-NS123101)
National Institute on Deafness and Other Communication Disorders (R01-DC014034)
Larry and Pamela Garlick
Article History
Received: 18 October 2023
Accepted: 7 January 2024
First Online: 18 January 2024
Competing interests
: The MGH Translational Research Center has clinical research support agreements with Neuralink, Synchron, Axoft, Precision Neuro, and Reach Neuro, for which L.R.H. provides consultative input. MGH is a subcontractor on an NIH SBIR with Paradromics. J.M.H. is a consultant for Neuralink and Paradromics, serves on the Medical Advisory Board of Enspire DBS and is a shareholder in Maplight Therapeutics. He is also an inventor on intellectual property licensed by Stanford University to Blackrock Neurotech and Neuralink. K.V.S. consulted for Neuralink and CTRL-Labs (part of Meta Reality Labs) and was on the scientific advisory boards of MIND-X, Inscopix and Heal. He was also an inventor on intellectual property licensed by Stanford University to Blackrock Neurotech and Neuralink. All other authors have no competing interests.